

MARKET
DYNAMIXREALTIME
DYNAMIXLAUNCH
DYNAMIXREALWORLD
DYNAMIXSPECIAL
TOPIX

SPECIAL TOPIX

Accelerated Approvals in Early AD (Leqembi)

Service Overview

Special Topix™: Accelerated Approvals in Early Alzheimer's Disease (Leqembi) Report (US) a single-wave report series that collects feedback from US neurologists and Alzheimer's disease specialists about their awareness, uptake, and anticipated usage of Eisai/Biogen's Leqembi, only the second approved anti-amyloid monoclonal antibody for early Alzheimer's disease. The report looks at brand perceptions, promotional activity, drivers and barriers to uptake, and the emerging diagnostic landscape in Alzheimer's disease.

Research Methodology

Sample

- n=73 U.S. neurologists and Alzheimer's disease specialists ; 20-minute online survey including open-ended questions
- Survey fielded March 3rd-7th, 2023
- n=5 30-minutes qualitative telephone interviews
- Interviews conducted March 13th - March 17th, 2023
- Participants paid an honorarium for participating

Key Report Content

Leqembi Awareness, Uptake, and Perceptions

- Are neurologists aware (aided and unaided) of the accelerated approval for Eisai/Biogen's Leqembi?
- What are neurologists' experience with Eisai/Biogen's Leqembi? Are they prescribing the drug currently or do they plan to begin in the near future?
- How do neurologists view the degree of advance, risk/benefit, and cost/benefit offered by Leqembi?
- What do neurologists anticipate will be the drivers and barrier to their use of the DMT?
- What are neurologists' perceptions of Eisai and Biogen's marketing of Leqembi?

Amyloid Diagnostics and ARIA

- What diagnostic tools are neurologists using or plan to use to confirm amyloid pathology and how burdensome are these tests?
- What testing tools do neurologists plan on employing in the future for their early AD patients?
- How concerned are neurologists with the risk of ARIA?
- How burdensome will monitoring patients for ARIA be for neurologists and patients? Will these burdens impact neurologists' ability to manage Leqembi patients?

Key Therapies Covered

- Eisai/Biogen's Leqembi

Report Timeline

- Final proprietary questions due: February 20th
- Report publication: March 30th

Key Service Features



Presentation: On-site or virtual presentation with custom insights tailored towards your brand



Ad hoc analysis: Access to analytics and insights team, frequency tables and summary statistics available upon request



List match: Call list match with target group analysis provided at no charge



Publication embargo: Advanced report release for subscribed clients, three-day embargo on public dissemination

For pricing and more information, please contact: info@spherixglobalinsights.com or call **+1 (484) 879-4284**